Having trouble accessing articles? Reset your cache.

Catalent adds another foothold in new modality manufacturing via takeout of cell therapy provider MaSTherCell

Catalent is building out its manufacturing capacity for new modalities via the $315 million acquisition of cell therapy company MaSTherCell, less than a year after the

Read the full 261 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE